Schrodinger (SDGR) announced that it is broadening and accelerating its initiative to expand the company’s computational platform to predict toxicology risk early in drug discovery. The goal of the ...
Schrödinger delivered strong Q1 results, with robust software growth and improving margins, despite a tough macro environment. Regulatory changes, especially the FDA's move away from animal testing, ...
NEW YORK--(BUSINESS WIRE)--Schrödinger, Inc. (Nasdaq: SDGR), whose physics-based computational platform is transforming the way therapeutics and materials are discovered, today announced that it is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback